ONTX was devalued by Zacks  from a “buy” score to a “hold” score in a research note provided to capitalists on Thursday, Zacks.com records.

According to Zacks, “Onconova Therapeutics, Inc. runs as a clinical-stage biopharmaceutical company. It concentrates on finding and creating tiny particle medicine candidates to deal with cancer. The Company‘s items under various phases of development include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

Several various other equities research analysts likewise recently talked about the business. Noble Financial reissued a “buy” rating and also issued a $11.00 cost goal on shares of Onconova Therapeutics in a report on Thursday, September 23rd. Guggenheim dropped their cost target on Onconova Therapeutics from $29.00 to $12.00 and set a “purchase” ranking on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 and also a twelve month high of $28.95. Business has a 50 day moving ordinary price of $2.90 as well as a two-hundred day moving ordinary price of $4.16. The business has a market cap of $46.76 million, a P/E proportion of -1.82 as well as a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last launched its quarterly revenues outcomes on Thursday, November 11th. The biopharmaceutical firm reported ($ 0.22) profits per share for the quarter, covering experts’ agreement price quotes of ($ 0.33) by $0.11. Onconova Therapeutics had an adverse return on equity of 59.78% as well as a negative net margin of 8,294.27%. The firm had profits of $0.06 million during the quarter, compared to the consensus estimate of $0.06 million. Throughout the very same quarter in the previous year, the firm published ($ 0.45) EPS. As a group, research experts anticipate that Onconova Therapeutics will certainly publish -1.18 EPS for the current year.

A variety of hedge funds have lately dealt shares of ONTX. GSA Resources Partners LLP bought a new setting in Onconova Therapeutics during the 3rd quarter worth $922,000. Hudson Bay Resources Administration LP acquired a new setting in shares of Onconova Therapeutics in the third quarter worth $635,000. Pura Vida Investments LLC purchased a new placement in shares of Onconova Therapeutics in the third quarter worth $575,000. CVI Holdings LLC acquired a brand-new position in shares of Onconova Therapeutics in the 3rd quarter worth $493,000. Lastly, Dimensional Fund Advisors LP bought a new placement in shares of Onconova Therapeutics in the second quarter worth $509,000. Hedge funds and also various other institutional investors own 13.36% of the company’s stock.

Regarding Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the identification and advancement of oncology therapeutics. It concentrates on uncovering and also establishing little molecule medication candidates to treat cancer. The firm was founded by Ramesh Kumar as well as E. Premkumar Reddy on December 22, 1998 and also is headquartered in Newtown, PA

. Obtain a complimentary copy of the Zacks research record on Onconova Therapeutics (ONTX).

For more details concerning research offerings from Zacks Investment Research, see Zacks.com.

This immediate information alert was produced by narrative scientific research innovation and also monetary information from Market in order to provide readers with the fastest and most accurate coverage. This tale was examined by Market’s content team prior to publication. 



Before you think about Onconova Therapeutics, you’ll want to hear this.

Market tracks Wall Street’s premier and also ideal performing research analysts as well as the stocks they recommend to their clients each day. Market has actually recognized the five stocks that top experts are silently whispering to their clients to get now prior to the broader market catches on … as well as Onconova Therapeutics wasn’t on the listing.

While Onconova Therapeutics currently has a “Buy” score amongst analysts, premier analysts think these 5 stocks are much better acquires.